MiNA works in collaboration with world leading research organisations across academic institutions and industry partners.

COLLABORATORS

In 2019 We Entered Into A Research Collaboration With AstraZeneca To Study saRNA Compounds In Metabolic Diseases
In 2019 We Entered Into A Research Collaboration With AstraZeneca To Study saRNA Compounds In Metabolic Diseases
In May 2017, Sosei Group Corporation made a strategic investment of £35m in MiNA. Sosei is an international biopharmaceutical company originating from Japan
In May 2017, Sosei Group Corporation made a strategic investment of £35m in MiNA. Sosei is an international biopharmaceutical company originating from Japan
In November 2017, Innovate UK awarded MiNA and LGC Link a grant to develop liver targeted gene activation therapies for the treatment of liver diseases
In November 2017, Innovate UK awarded MiNA and LGC Link a grant to develop liver targeted gene activation therapies for the treatment of liver diseases
In 2015 we entered in a multi-year collaborative research agreement with Imperial College London to discover and develop new saRNA medicines
In 2015 we entered in a multi-year collaborative research agreement with Imperial College London to discover and develop new saRNA medicines
Since 2014 we have been collaborating with the Bioinformatics core facility at NTNU Trondheim to discover new saRNA compounds
Since 2014 we have been collaborating with the Bioinformatics core facility at NTNU Trondheim to discover new saRNA compounds
Since 2018 we have been working with investigators at the University of Liverpool on the up-regulation of gene targets using our saRNA technology
Since 2018 we have been working with investigators at the University of Liverpool on the up-regulation of gene targets using our saRNA technology
In 2018 we entered into a multi-year collaborative research agreement with the Wistar Institute to study the immunological effects of MiNA compounds in cancer treatment
In 2018 we entered into a multi-year collaborative research agreement with the Wistar Institute to study the immunological effects of MiNA compounds in cancer treatment

We are seeking new R&D partners in academic research and
biopharmaceutical drug development in the following areas:

Opportunities to evaluate pharmacology of MTL-CEBPA as a combination agent in both pre-clinical studies and clinical development including clinical collaborations in immuno-oncology.

Drug discovery opportunities against new disease targets especially in immuno-oncology, immunology and metabolic diseases.

New, scalable, delivery technologies, administered systemically or locally, that can extend the in vivo activity of our saRNA compounds to tissue that are currently inaccessible.

By continuing to use this site you are agreeing only to the use of cookies that are strictly necessary for the running of our website. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close